about
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysisSpanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM studyIntrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), SpanA predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trialOvereating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM studyA Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerHER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisAlkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain studyChanges in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trialAssociation between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer typesMultiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete responseRibociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialPhase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 studyDevelopment and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q"Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
P50
Q33419870-B7EE5EC2-2A76-4E13-BCBE-27B68C0EC2F0Q34283751-BD47571F-ACD5-4EE8-B4A8-C74CBF271383Q42506362-71FE328F-F433-4F74-A84A-4988223E4AC2Q47579480-487B1A79-4ACA-4C5D-8082-4CB956FA818AQ50089472-74008E44-803D-4BBF-B0DC-560DE327909AQ54979063-7F507C93-5018-4C35-A79E-F2E877BCD4F1Q60913102-343FCA25-54C8-4AF1-9BB5-CBE74B44D19DQ64054652-7E829F55-7079-4976-B6DE-DB0F12EE38DEQ64085234-1EF1E637-310E-4D76-A18D-5E442F740909Q89446547-8BC13156-5060-43DB-B33E-0A2FA0B6088BQ90550755-8368A550-6F88-45AC-BBE0-0819EB863F20Q91134928-EF26EE44-77C1-4B6D-B8E8-05C30F0BA191Q91233906-63532131-E07E-4BAC-94F5-2D57C448D795Q91897011-16CB800D-5DFB-48E2-B5E9-59DDFACF9A46Q91981752-0BD8723E-4523-4B17-8897-D400FE83BA86Q92452992-4E2C6DB8-D697-4712-BDB1-3BB482542D62Q92665738-E8DEB889-2918-441C-8E40-83423D384AB7Q92782415-45A7D9EA-0C16-4669-9DA2-5013C63235B4
P50
description
researcher
@en
name
Montserrat Muñoz
@en
type
label
Montserrat Muñoz
@en
prefLabel
Montserrat Muñoz
@en
P31
P496
0000-0001-7772-1437